{"entity":{"id":"idea-atc-triplet-io","kind":"idea","name":"BRAF/MEK plus PD-1 blockade as standard for BRAF-mutant anaplastic thyroid cancer","aka":[],"tldr":"Add immunotherapy to the two targeted pills in the most aggressive thyroid cancer, because the combination has produced multi-year survivors in early series.","summary":"The idea is to make dabrafenib and trametinib plus pembrolizumab the standard first-line treatment for BRAF V600E-mutant anaplastic thyroid cancer. Anaplastic thyroid cancer is immunologically hot relative to differentiated cancers, with high PD-L1 expression and mutational burden, and targeted therapy induces rapid antigen release that checkpoint blockade can exploit. MD Anderson series of the triplet report multi-year survivors and longer overall survival than the doublet, building on the anaplastic cohort of the ROAR trial. The hypothesis is that adding pembrolizumab extends overall survival; given the rarity of the disease, the test is an international randomised phase 2 of doublet versus triplet with survival at one year as primary endpoint.","asOf":"2026-09-07","links":[{"label":"ClinicalTrials.gov NCT02034110: ROAR (anaplastic thyroid cancer cohort)","url":"https://clinicaltrials.gov/study/NCT02034110"}],"tags":[],"related":[],"cancers":["thyroid"],"sections":[],"technologies":[],"targets":["braf","pd1"],"drugs":["dabrafenib-trametinib","pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["roar-atc"],"people":[],"bottlenecks":[],"keyPapers":["paper-braf-thyroid-n-engl-j-med-2015","paper-braf-thyroid-endocr-relat-cancer-2005","paper-braf-thyroid-endocr-rev-2007"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Adding pembrolizumab to dabrafenib-trametinib extends OS in BRAF V600E ATC.","rationale":"Targeted therapy induces rapid immunogenic response and antigen release; ATC is immunologically hot relative to differentiated cancers.","test":"International randomised phase 2 (doublet vs triplet) given rarity, with OS at 12 months as primary endpoint.","maturity":"early-clinical"},"route":"/ideas/idea-atc-triplet-io/","neighbours":{"cancer":[{"id":"thyroid","kind":"cancer","name":"Thyroid cancer","route":"/cancers/thyroid/"}],"target":[{"id":"braf","kind":"target","name":"BRAF","route":"/targets/braf/"},{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"}],"drug":[{"id":"dabrafenib-trametinib","kind":"drug","name":"Dabrafenib + trametinib","route":"/drugs/dabrafenib-trametinib/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"trial":[{"id":"roar-atc","kind":"trial","name":"ROAR (anaplastic thyroid cancer cohort)","route":"/trials/roar-atc/"}],"paper":[{"id":"paper-braf-thyroid-endocr-rev-2007","kind":"paper","name":"BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications","route":"/key-papers/paper-braf-thyroid-endocr-rev-2007/"},{"id":"paper-braf-thyroid-endocr-relat-cancer-2005","kind":"paper","name":"BRAF mutation in thyroid cancer","route":"/key-papers/paper-braf-thyroid-endocr-relat-cancer-2005/"},{"id":"paper-braf-thyroid-n-engl-j-med-2015","kind":"paper","name":"Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations","route":"/key-papers/paper-braf-thyroid-n-engl-j-med-2015/"}]}}